Achieve Life Sciences Completes Stock Offering
SEATTLE and VANCOUVER, British Columbia — Achieve Life Sciences, Inc. (NASDAQ: ACHV), an innovative late-stage specialty pharmaceutical company, recently announced a significant milestone by completing the closing of an underwritten public offering. This offering involved 15 million shares of common stock, providing the company with substantial funds totaling $45 million before expenses. The accompanying common warrants allow for the purchase of an additional 16.77 million shares at $3.00 each.
Funding Future Developments
The proceeds from this strategic offering will play a crucial role in advancing the company's primary focus: the potential U.S. Food and Drug Administration (FDA) approval of cytisinicline, a promising treatment for nicotine dependence, particularly in smoking cessation. Achieve’s management is optimistic about what these funds will enable in terms of their ongoing developmental and operational plans.
Expertise in the Offering Process
In successfully steering this financial endeavor, Achieve collaborated with Citizens Capital Markets and Raymond James, both of whom served as joint book-running managers. Meanwhile, Lake Street Capital Markets, LLC provided financial advising services, enhancing the strategic execution of this capital raising endeavor.
The Role of Cytisinicline
Achieve Life Sciences is dedicated to addressing the ongoing nicotine dependence crisis through the development and commercialization of cytisinicline. In June 2025, the company took a noteworthy step by submitting a New Drug Application to the FDA. This application was built on a strong foundation comprising two successful Phase 3 studies, accompanied by an open-label safety study which has been fully enrolled, highlighting the drug’s potential.
Addressing Smoking and Vaping Issues
The impact of tobacco use is profound, affecting millions in the U.S., where approximately 29 million adults are regular smokers. The ramifications of smoking lead to over eight million deaths globally each year, with smoking being the leading cause of preventable death. Achieve's commitment extends to tackling these challenges through cytisinicline, which has also been recognized by the FDA with Breakthrough Therapy designation. This accolade is indicative of the critical need for a dedicated treatment for nicotine e-cigarette cessation, given the rising numbers of e-cigarette users among both adults and the youth.
The Science Behind Cytisinicline
Cytisinicline, a plant-derived alkaloid, actively engages with the nicotinic acetylcholine receptor in the brain. This interaction has shown promise in mitigating nicotine cravings and reducing the satisfaction associated with nicotine consumption. However, it is essential to note that cytisinicline is classified as an investigational product and is currently under development without FDA approval for any usage in the United States.
Commitment to Transparency
Importantly, Achieve Life Sciences underscores that this announcement does not constitute an offer for any securities sale but serves to inform the public about the significant strides the company is making towards addressing nicotine dependence and enhancing public health outcomes. Their dedication to transparency reflects a commitment to engaging with stakeholders while managing expectations regarding the complexities of drug approval processes.
Frequently Asked Questions
What is the significance of Achieve's recent stock offering?
The closing of the stock offering provides $45 million in funding, crucial for advancing the cytisinicline project.
What is cytisinicline?
Cytisinicline is a plant-based treatment aimed at aiding smoking cessation by interacting with nicotine receptors in the brain.
How does cytisinicline help with nicotine dependence?
Cytisinicline works by reducing cravings and satisfaction associated with nicotine products, thus helping users quit smoking or vaping.
What steps is Achieve Life Sciences taking towards FDA approval?
Achieve has submitted a New Drug Application based on successful clinical studies, aiming for FDA marketing approval.
Who were the financial partners involved in the stock offering?
Citizens Capital Markets and Raymond James were the joint book-running managers, with Lake Street Capital Markets as financial advisor.
